SMR3A

Across TCGA pan-cancer cohorts, SMR3A mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SMR3A data layer compared with 11 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SMR3A mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SMR3A expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

PDAC, LUAD, and HNSC are the cancer types where SMR3A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	II,III,IV	0.539	0.331	.006	30	view →
LUAD	OS	Quartile	All	0.443	1.000	.007	19	view →
HNSC	DFS	Tertile	II,III,IV	1.000	0.845	.031	8	view →
LSCC	OS	Median	II,III,IV	0.901	1.000	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SMR3A–PDAC (DFS)

Open the PDAC breakdown →